Dr. Charles Keller and the Children’s Cancer Therapy Development Institute (ww.cc-tdi.org) is excited to announce a strategic collaboration with Dr. Christopher Vakoc at the Cold Spring Harbor Laboratory to develop new treatments for the childhood muscle cancer, rhabdomyosarcoma. This joint effort between the Vakoc lab and the Keller laboratory (at cc-TDI) explores a new class of therapeutic targets using the most advanced genetic tools… those specially developed by the Vakoc laboratory to study leukemia. This work is made possible by a coalition of community-based rhabdomyosarcoma advocates, who know only too well the need for new approaches to this disease. We are grateful for their partnership.
Click here to read the newspaper article.
cc-TDI is a new, non-profit research laboratory focused on bridging scientific discovery and the initiation of clinical trials. The lab’s goal is to provide critical evidence-based testing for the selection of new drugs to be used in childhood cancer clinical trials, this seeding pediatric Phase I and Phase II trials.